KML Vision GmbH

Name ›

Address/P.O. Box › Postal Code/City › Country › Contact Person ›

Telephone › Fax › Email › Website › Social Media › Number of Employees › Founded (year) › Type of Laboratory ›

Areas of Activity ›

ITM Isotope Technologies Munich SE

Lichtenbergstrasse 1 85748 Garching / Munich Germany Julia Hofmann / Susanne Karlsson Corporate Communications +49-89-329-8986-6000 +49-89-329-8986-6061 communications@itm-radiopharma.com www.itm-radiopharma.com

LI

370 2004 Radiopharmaceutical biotech company

| Oncology | Precision Medicine | Targeted Radionuclide Therapy | Nuclear Medicine

Targeted cancer diagnostics and therapies

ITM, a radiopharmaceutical biotech company, is dedicated to providing the most precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians and partners through excellence in development, production and global supply. With patient benefit as the driving principle, ITM is advancing a broad pipeline combining its medical radioisotopes with targeting molecules to develop precision oncology treatments. ITM is leveraging its leadership and nearly two decades of radiopharma expertise combined with its worldwide network to enable nuclear medicine to reach its full potential for helping patients live longer and better.

Targeted Radionuclide Therapy or Peptide Receptor Radionuclide Therapy (PRRT) is an emerging class of cancer therapeutics, in which radiation is delivered directly to the tumor while minimizing radiation exposure to normal tissue. In contrast to conventional external radiotherapy, Targeted Radionuclide Therapy is defined by the intravenous infusion of a radiopharmaceutical. Targeted radiopharmaceuticals are created by linking a therapeutic radioisotope to a targeting molecule (e.g., peptide, antibody, small molecule) that can precisely recognize tumor cells and bind to tumor-specific characteristics. As a result, the radioisotope accumulates at the tumor site and decays, releasing a small amount of ionizing radiation, thereby destroying tumor tissue. The highly precise localization enables targeted treatment with minimal impact to healthy surrounding tissue.

Often, the targeting molecule can be used in a “theranostic” approach for both therapeutics and diagnostics. For diagnosis, the targeting molecule is linked with a diagnostic radioisotope, for therapy with a therapeutic radioisotope. This allows tumors and metastases to be both precisely localized at an early stage, and subsequently treated following the same mechanism.

ITM is developing a proprietary portfolio and precision oncology pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine tumors, glioblastoma, osteosarcoma and bone metastases, prostate cancer, as well as folate receptor α positive tumors like lung, ovarian or breast cancer. To validate the Targeted Radionuclide Therapy approach, efficacy and safety of the lead candidate n.c.a. 177Lu-Edotreotide are currently being compared to standard treatments for patients with neuroendocrine tumors of gastroenteric or pancreatic origin in two Phase III clinical trials, COMPETE & COMPOSE.

The unique combination of ITM’s longstanding expertise, high-quality radioisotopes and global supply network enables ITM to develop new Targeted Radionuclide Therapy based treatment options for hard-to-treat cancer indications. ITM strives to positively impact the treatment algorithm currently in place for solid tumors and make a tangible impact in improving the lives and treatment outcomes of cancer patients.

For more information about ITM, please visit: www.itm-radiopharma.com